Colazal Related Published Studies
Well-designed clinical trials related to Colazal (Balsalazide)
Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. [2009.11]
Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. [2009.11]
Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. [2005.12.01]
Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. [2004.11]
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. [2004.05.15]
Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. [2004.02.15]
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. [2002.12]
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. [2002.06]
A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. [2002.01]
A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. [2002.01]
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. [2001.12]
Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. [1998.12]
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. [1998.01]
Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. [1992.10]
Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. [1992.08]
Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. [1988.06]
Well-designed clinical trials possibly related to Colazal (Balsalazide)
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. [2009.06]
Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases. [2007]
Other research related to Colazal (Balsalazide)
Unilateral balsalazide-induced eosinophilic pneumonia in an ulcerative colitis patient. [2010.09]
Balsalazide in treating colonic diseases. [2009.12]
Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. [2009.10]
Chemoprevention of Colonic Polyps with Balsalazide: An Exploratory, Double-Blind, Placebo-Controlled Study. [2009.09.11]
Safety, Efficacy, and Pharmacokinetics of Balsalazide in Pediatric Patients With Mild-to-Moderate Active Ulcerative Colitis: Results of a Randomized, Double-blind Study. [2009.07.21]
Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. [2009.04]
[Effect of balsalazide on intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice] [2009.03]
Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon. [2008.09]
Comparison of Mesalazine and Balsalazide in Induction and Maintenance of Remission in Patients with Ulcerative Colitis: A Meta-Analysis. [2008.08.06]
Balsalazide disodium for the treatment of ulcerative colitis. [2008.04]
Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. [2007.09]
Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. [2007.03.28]
A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis. [2006.10]
Safety of balsalazide therapy in the treatment of inflammatory bowel disease. [2005.06]
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. [2005.03]
Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. [2002]
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. [2001.11]
Review article: balsalazide therapy in ulcerative colitis. [2001.10]
Balsalazide. [1998.07]
Other possibly related research studies
The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. [2004.03]
Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. [2004.01.15]
The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. [2003.09]
Review article: maintenance treatment of Crohn's disease. [2003.06]
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria. [2003.01]
Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. [2002]
Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine. [1998.12]
Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats. [1998.11]
Inhibition by aminosalicylates of lipid peroxidation in large intestinal mucosa after mesenteric ischemia/reperfusion in the rat. [1997.10]
[Pharmacological studies of BX661A. 5-[4-(2-carboxyethylcarbamoyl)-phenylazo]-salicylic acid disodium salt dihydrate (1). Therapeutic effects on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) model in rats] [1997.02]
Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. [1992.02]
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. [2005.11]
Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. [2005.06]
Mesalamine delivery systems: do they really make much difference? [2005.01.06]
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. [2005.01.06]
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. [2003.01]
New developments in the treatment of inflammatory bowel disease. [2002.03]
Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. [2001.04]
Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. [1999.11]
Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. [1999.03]
5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation. [1989.06]
Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. [2006.03]
VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. [2006]
How important is onset of action in ulcerative colitis therapy? [2005]
Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature. [2006.09]
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. [2006.10]
Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. [2008.02]
A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis. [2008.09.04]
Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet? [2008.09]
Treatment Options for Uncomplicated Diverticular Disease of the Colon. [2009.07.30]
[Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis] [2009.03.01]
A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. [2009.06]
Treatment options for uncomplicated diverticular disease of the colon. [2009.10]
Balsalazine decreases intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice. [2009.07]
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. [2012]
|